AXIOS August 16, 2024
Caitlin Owens

Unless you were under a rock, you saw Thursday’s news that Medicare negotiated a better deal than the private market for some of the program’s top-selling drugs.

Why it matters: So what? How meaningful is that difference, and what will the longer-term effects be?

  • Some seniors will likely pay less out of pocket for drugs (that’s a whole different topic), and that obviously matters to patients. But how pharma interprets the negotiated prices and reacts to them will have a huge impact on future drug development.

Our thought bubble: Democrats are thrilled, Republicans are appalled. The drug industry is complaining publicly but telling investors everything is fine.

  • For all of the uproar this law caused when it...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article